NASD · Healthcare · Biotechnology · USA
Krystal Biotech Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Krystal Biotech is a biotechnology company that discovers, develops, manufactures and commercializes genetic medicines using its proprietary HSV-1 based gene therapy platform. Its first commercial product, VYJUVEK, treats dystrophic epidermolysis bullosa and is approved in the United States, European Union and Japan. The company operates two in-house manufacturing facilities.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Krystal Biotech Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.
Leak Score: 49/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on KRYS yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-30 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
49 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.